A less intensive combination of paclitaxel and carboplatin in advanced non-small cell lung cancer patients who have aged 60 years or more and has a poor performance status

Korean Journal of Internal Medicine

Volumn 19, Issue 2, 2004, Pages 109-113

  Min, Young Joo ^a   Ahn, Jong Joon ^a   Noh, Young Ju ^a   Cha, Hee Jeong ^a   Suh, Jae Hee ^a   Jung, Jong Pil ^a   Park, Chang Ryul ^a   Jeong, Ae Kyung ^a   Park, Jae Hoo ^a   Lee, Ki Man ^b,c  

^a University of Ulsan College of Medicine   (South Korea)

^b Chungbuk National University   (South Korea)

^c Chungbuk National University College of Medicine   (South Korea)

Author keywords

Carboplatin; Elderly; Non small Cell lung Cancer; Paclitaxel

Indexed keywords

CARBOPLATIN; PACLITAXEL;

AREA UNDER THE CURVE; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; HUMAN; LUNG NON SMALL CELL CANCER; PERFORMANCE;

EID: 24144474989     PISSN: 12263303     EISSN: None     Source Type: Journal    
DOI: 10.3904/kjim.2004.19.2.109     Document Type: Article

References (14)

1. Lee CT. Epidemiology of lung cancer in Korea. Cancer Res Treat 34:3-5, 2002
2. Shin HR, Ahn YO, Bae JM, Shin MH, Lee DH, Lee CW, Ohrr H, Ahn DH, Ferlay J, Parkin DM, Oh DK, Park JG. Cancer incidence in Korea. Cancer Res Treat 34:405-408, 2002
3. le Chevalier T, Brisgand D, Douillard JY, Pujol JL, Alberola V, Monnier A, Riviere A, Lianes P, Chomy P, Cigolari S, Gottfried M, Ruffie P, Panizo A, Gaspard MH, Ravaioli A, Besenval M, Besson F, Martinez A, Berthaud P, Tursz T. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer results of a European multicenter trial including 612 patients. J Clin Oncol 12:360-367, 1994
4. Bonomi P, Kim K, Fairclough D, Cella D, Kugler J, Rowinsky E, Jiroutek M, Johnson D. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin. J Clin Oncol 18:623-631, 2000
5. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346:92-98, 2002
6. Gatzemeier U, Rusell R, Betticher D, Keppler U, Macha HN, Pirker R, Berthet P, Breau JL, Bogaerts J, Gallant G. Randomised pan-European trial comparing paclitaxel (TAX)/carboplatin (CAR) versus paclitaxel/cisplatin (CIS) in advanced non-small cell lung cancer (NSCLC). Eur J Cancer 35(suppl 4):246, 1999
7. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, van Glabbeke MV, van Oosterom TA, Christian MC, Gwyther SG. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205-216, 2000
8. 2) plus carboplatin (6 AUC) in advanced non-small cell lung cancer (NSCLC). Ann Oncol 11:799-805, 2000
9. Glorieux P, Ortmanns P, van den Bulcke J, Dewispelaere B, Petrick M, Canon J, Degives R, Degraeve D, Janssens E, van Hulle J, Grauwels D, Schallier D. Multi-center study with paclitaxel/carboplatin (PC) in advanced or metastatic non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 19:533a, 2000
10. Klastersky J, Sculier JP, Bureau G, Libert P, Ravez P, Vandermoten G, Thiriaux J, Lecomte J, Cordier R, Dabouis G, Brohee D, Themelin L, Mommen P. Cisplatin vs cisplatin plus etoposide in the treatment of advanced non-small cell lung cancer. J Clin Oncol 7:1087-1092, 1989
11. Albain KS, Crowley JJ, LeBlanc M, Livingston RB. Survival determinants in extensive-stage non-small cell lung cancer. J Clin Oncol 9:1618-1626, 1991
12. Bonomi PD, Finkelstein DM, Ruckdeschel JC, Blum RH, Green MD, Mason B, Hahn R, Tormey DC, Harris J, Comis R, Click J. Combination chemotherapy vs single agents followed by combination chemotherapy in stage IV non-small cell lung cancer. J Clin Oncol 7:1602-1613, 1989
13. Luedke DW, Einhorn L, Omura GA, Sarma PR, Bartolucci AA, Birch R, Greco FA. Randomized comparison of two combination regimen vs minimal chemotherapy in non-small cell lung cancer. J Clin Oncol 8:886-891, 1990
14. Miller TP, Chen TT, Coltman CA Jr, O'Bryan RM, Vance RB, Weiss GB, Fletcher WS, Stephens RL, Livingston RB. Effect of alternating combination chemotherapy on survival of ambulatory patients with metastatic large cell and adenocarcinoma of the lung. J Clin Oncol 4:502-508, 1986